Long-Term Follow-up Study of Century Therapeutics Cellular Therapy in Hematological Malignancies, Solid Tumors, and Autoimmune Diseases

The primary objective of this study is to conduct a long-term follow-up of subjects who have previously been treated with a Century Therapeutics cellular therapy product. This follow-up is crucial for assessing the sustained efficacy and safety of the therapy in individuals with **hematological or solid tumor malignancies** or **autoimmune diseases**. Monitoring these patients over an extended period will provide valuable insights into the long-term outcomes and potential late-onset effects of the treatment.

The clinical trial involves a total of **48 participants** diagnosed with **hematological or solid tumor malignancies** or **autoimmune diseases**. The study population includes both male and female subjects, encompassing an **age range** that includes both adults and adolescents. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The selection process aimed to ensure a representative sample of individuals affected by the specified medical conditions.

The clinical trial is designed to evaluate the long-term effects of a cellular therapy product in subjects with **hematological or solid tumor malignancies** or **autoimmune diseases**. This study is a Phase 3 trial, which is expected to commence recruitment on July 28, 2025, and conclude by April 10, 2032. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be involved in the study for an extended period, with the duration of individual participation varying based on the specific protocol requirements and the participant's response to the treatment.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits at regular intervals to monitor their health status, treatment response, and any adverse events. These visits are crucial for collecting data on the long-term safety and efficacy of the therapy. The end-of-study visit marks the conclusion of a participant's involvement, where final assessments are conducted to gather comprehensive data on the treatment outcomes.

Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial is structured to ensure participant safety and the integrity of the data collected. The study's methodology and design are aligned with regulatory standards to provide robust evidence on the therapy's long-term impact on the specified medical conditions.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the data. As such, these aspects cannot be detailed in the context of this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 28, 2025, with an estimated completion date of April 10, 2032. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.